With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar.
The stocks highlighted below are just a starting sample, and the full screen surfaced 5 more companies with equally compelling AI healthcare narratives that are not covered in this article. To identify which opportunities best fit your approach, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze these AI healthcare stocks with confidence.
Haleon (LSE:HLN)
Haleon is a global consumer healthcare company behind brands like Sensodyne, Centrum, Panadol and Advil, and it is now working with Microsoft to build AI driven analytics and digital tools into how it develops, markets and distributes these products. The business is diversified across North America with about £3.8b of revenue, EMEA and Latam with about £4.7b, and Asia Pacific with about £2.6b, which gives its AI efforts a broad data and execution base. With a market cap of around £31.1b, Haleon gives investors exposure to everyday health brands with an emerging AI angle rather than a pure play on AI healthcare.
Investors looking at Haleon today are getting a large scale consumer healthcare company that is starting to plug AI into real world problems like supply chain, marketing and product development through its partnership with Microsoft. That AI story sits on top of established brands and global reach, but there are genuine questions around rising regulatory costs, debt levels and whether the product pipeline keeps pace with changing consumer tastes. The interest lies in whether AI supported insights and efficiency can help protect margins, support emerging market expansion and make that brand portfolio work harder. The details of how that balance plays out are where this story becomes much more interesting for long term investors.
Haleon's AI push could be the missing link between everyday brands and smarter margins, but the real story sits in the balance of debt, regulation and cash flow quality in the Haleon financial health report
IXICO (AIM:IXI)
IXICO is a London based medical data analytics company that runs AI enabled neuroimaging for clinical trials in Alzheimer's, Parkinson's, Huntington's and other neurological diseases through its IXICO platform and imaging contract research services. The business currently generates about £7.3 million of revenue from Medical Labs and Research work that includes radiological reads, volumetric MRI, PET and SPECT analysis and advanced MRI based biomarkers for drug developers. With a market cap of about £16 million, IXICO is a much smaller AI healthcare stock than many peers, which can make both the upside and the business risks feel more amplified.
IXICO may appeal to investors who want direct exposure to AI being used on real patient brain scans rather than back office efficiency tools. Its IXICO platform and Medidata partnership plug AI into trial grade imaging for complex neurological diseases. The company reported upgraded revenue guidance in 2026 and new ties to leading brain research experts and institutions. However, IXICO remains loss making, earnings are expected to decline, and recent shareholder dilution and reliance on higher risk funding raise questions about how easily it can fund growth. That mix of specialist AI capability, small size and financial pressure is a key part of the IXICO story for long term investors.
IXICO's AI brain imaging story is small in scale but big in ambition, with funding pressure and losses shaping the picture. Get the full risk and upside context in the 1 key reward and 3 important warning signs (2 are major!)
AstraZeneca (LSE:AZN)
AstraZeneca is a global biopharmaceutical company focused on prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases. Its AI credentials are anchored in an agreement with Tempus and Pathos to build a large multimodal oncology foundation model that combines imaging, genomics and clinical data for cancer care. The company generated about $61.4b of revenue from pharmaceuticals and has a market cap of roughly £186.2b. This gives its AI oncology work substantial scale but means it currently sits alongside a broad drug portfolio rather than dominating it.
AstraZeneca provides exposure to a broad oncology and specialty medicine portfolio that is now tied directly into AI through its Tempus and Pathos collaboration. This collaboration aims to use multimodal data to refine cancer diagnosis and treatment selection. That AI angle is layered on top of sizeable pharmaceutical revenue and a large pipeline that has recently delivered approvals and licensing deals in areas such as HER2 breast and lung cancer. However, the company also faces pressure from patent expiries, price controls and high R&D spend. For investors who want a large cap pharma with a concrete AI oncology project rather than a pure software stock, a key consideration is how far that data advantage can influence pricing power, trial efficiency and earnings resilience.
AstraZeneca's AI oncology push and broad drug portfolio could be telling a different growth story than many investors assume. Get the full picture in the analysis report for AstraZeneca for one detail that may change how you view the risk reward balance.
Seeking Alternatives Before The Crowd Moves
Fresh stock ideas can gain breakout momentum quickly, and by the time headlines catch up, the cleanest entry points may be gone. Check these curated screens while it still matters and get in early.
-
Spot potential turnarounds before sentiment flips by scanning a curated group of 8 high quality undiscovered gems that are still under the radar for now.
-
Target resilience when markets wobble by reviewing a hand picked list of solid balance sheet and fundamentals (19 results) that could help you stay on the front foot.
-
Ride structural shifts in automation by tracking carefully filtered 36 robotics and automation stocks that may benefit if industrial spending keeps moving toward smarter systems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
